Skip to main content

Table 6 Multivariate analysis for patients receiving SRT (n = 2048)

From: Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis

  Hazard Ratio 95% Confidence Interval p-value
Sex Male 1.00 Ref 0.001
Female 0.83 0.75–0.92
Age 18–59 1.00 Ref 0.058
60–69 1.07 0.95–1.22
70–79 1.2 1.04–1.38
80+ 1.24 0.96–1.58
Comorbidity 0 1.00 Ref 0.062
1 0.99 0.87–1.13
> 2 1.25 1.03–1.5
Histology Adenocarcinoma 1.00 Ref < 0.001
Non-adenocarcinoma 1.31 1.17–1.46
Race White 1.00 Ref 0.538
Non-white 1.05 0.91–1.21
Insurance Uninsured 1.00 Ref 0.582
insured 0.92 0.69–1.24
Facility Type Academic 1.00 Ref 0.088
Nonacademic 1.1 0.99–1.22
Systemic Therapy Chemotherapy 1.00 Ref 0.031
Immunotherapy 0.82 0.69–0.98